Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $55.50.

Several research analysts recently commented on the company. Weiss Ratings reissued a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Lucid Cap Mkts raised Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th.

Tvardi Therapeutics Trading Down 2.2%

Tvardi Therapeutics stock opened at $3.93 on Monday. The firm has a market capitalization of $36.86 million, a P/E ratio of -0.41 and a beta of 0.14. Tvardi Therapeutics has a twelve month low of $3.50 and a twelve month high of $43.65. The stock’s fifty day simple moving average is $4.08 and its 200-day simple moving average is $12.40.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Arax Advisory Partners increased its position in shares of Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $43,000. HRT Financial LP acquired a new position in shares of Tvardi Therapeutics during the fourth quarter worth $47,000. Finally, XTX Topco Ltd acquired a new position in shares of Tvardi Therapeutics during the fourth quarter worth $55,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.